Amalgamated Bank Eagle Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$4.26 - $6.51 $2,360 - $3,606	-554 Reduced 58.44%	394 $2,000
Q4 2023 Feb 06, 2024	SELL	$4.63 - $15.21 $541 - $1,779	-117 Reduced 10.99%	948 $5,000
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $61,948 - $111,290	-3,492 Reduced 76.63%	1,065 $20,000
Q1 2023 May 02, 2023	SELL	$25.06 - $34.09 $2,681 - $3,647	-107 Reduced 2.29%	4,557 $129,000
Q4 2022 Feb 10, 2023	SELL	$24.98 - $39.77 $12,365 - $19,686	-495 Reduced 9.59%	4,664 $136,000
Q3 2022 Nov 09, 2022	SELL	$26.42 - $47.12 $3,883 - $6,926	-147 Reduced 2.77%	5,159 $136,000
Q2 2022 Aug 15, 2022	BUY	$41.26 - $51.35 $412 - $513	10 Added 0.19%	5,306 $236,000
Q1 2022 Jun 30, 2022	SELL	$44.58 - $52.6 $15,157 - $17,884	-340 Reduced 6.03%	5,296 $262,000
Q4 2021 Feb 15, 2022	SELL	$45.82 - $56.9 $12,096 - $15,021	-264 Reduced 4.47%	5,636 $287,000
Q3 2021 Oct 29, 2021	SELL	$43.79 - $55.78 $4,247 - $5,410	-97 Reduced 1.62%	5,900 $329,000
Q2 2021 Aug 16, 2021	BUY	$36.86 - $44.5 $221,049 - $266,866	5,997 New	5,997 $257,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $6.77M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.